Opinion
Video
AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis
A panel of expert oncologists explore the ongoing AFFIRM-AL trial, examining birtamimab in patients with a diagnosis of Mayo stage IV AL amyloidosis.
This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.
Current advancements in amyloidosis treatment involve critical phase 3 trials evaluating birtamimab and standard care for stage 4 cardiac amyloidosis. These trials are pivotal for potential drug licensing and moving the field forward. The ongoing AFFIRM-AL trial, specifically for patients with Mayo stage IV disease, aims to assess the impact of antifibril antibodies alongside standard care therapies like cyclophosphamide-bortezomib-dexamethasone (CyBorD) and a CD38 antibody. The panelists are eagerly anticipating trial results, hoping for improved hematologic and organ responses simultaneously, which would address the current lag in organ response. Recognizing the importance of these trials, clinicians’ focus on untreated patients reflects lessons learned from earlier studies, emphasizing statistical relevance and higher potential benefits. The experts emphasize accessing these trials at specialized centers for collecting crucial data and understanding potential benefits for patients.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
